ATE303369T1 - Glucocorticoid rezeptor modulatoren - Google Patents

Glucocorticoid rezeptor modulatoren

Info

Publication number
ATE303369T1
ATE303369T1 AT01308789T AT01308789T ATE303369T1 AT E303369 T1 ATE303369 T1 AT E303369T1 AT 01308789 T AT01308789 T AT 01308789T AT 01308789 T AT01308789 T AT 01308789T AT E303369 T1 ATE303369 T1 AT E303369T1
Authority
AT
Austria
Prior art keywords
glucocorticoid receptor
compounds
present
receptor modulators
provides
Prior art date
Application number
AT01308789T
Other languages
English (en)
Inventor
Kevin Kun Liu
Bradley P Morgan
Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE303369T1 publication Critical patent/ATE303369T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01308789T 2000-10-30 2001-10-16 Glucocorticoid rezeptor modulatoren ATE303369T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24430200P 2000-10-30 2000-10-30

Publications (1)

Publication Number Publication Date
ATE303369T1 true ATE303369T1 (de) 2005-09-15

Family

ID=22922191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01308789T ATE303369T1 (de) 2000-10-30 2001-10-16 Glucocorticoid rezeptor modulatoren

Country Status (9)

Country Link
US (1) US6852719B2 (de)
EP (1) EP1201660B1 (de)
JP (1) JP2002193955A (de)
AT (1) ATE303369T1 (de)
BR (1) BR0104834A (de)
CA (1) CA2360313C (de)
DE (1) DE60113032T2 (de)
ES (1) ES2246292T3 (de)
MX (1) MXPA01011108A (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
JP2006508042A (ja) * 2002-07-18 2006-03-09 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体の修飾物質および方法
AU2003299311A1 (en) * 2002-12-18 2004-07-09 University Of Zurich Treatment of neuro-psychiatric disorders
US7625921B2 (en) * 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7576076B2 (en) * 2004-07-02 2009-08-18 Corcept Therapeutics, Inc. Modified pyrimidine glucocorticoid receptor modulators
US20060154981A1 (en) * 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
WO2006078577A1 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
US7820674B2 (en) * 2005-01-19 2010-10-26 Merck, Sharp & Dohme Corp. Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
US8017775B2 (en) * 2005-09-14 2011-09-13 Santen Pharmaceutical Co., Ltd. 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
CN101400659B (zh) 2006-03-14 2012-02-29 参天制药株式会社 具有糖皮质激素受体结合活性的新型1,2,3,4-四氢喹喔啉衍生物
KR20090086539A (ko) * 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
DK2114970T3 (da) 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
EP2151436B1 (de) * 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Neuartiges 1,2,3,4-tetrahydrochinoxalin-derivat mit einer als substituent eingefügten phenylgruppe, die eine schwefelsäureesterstruktur oder eine schwefelsäureamidstruktur aufweist, sowie mit glucocorticoidrezeptor-bindungswirkung
TWI510240B (zh) 2008-05-12 2015-12-01 由具有取代氧基之2,2,4-三甲基-6-苯基-1,2-二氫喹啉衍生物組成之糖皮質激素受體激動劑
BRPI0917212A2 (pt) 2008-07-28 2015-11-10 Pfizer compostos de fenantrenona, seus usos na preparação de composições, e composições compreendendo os referidos compostos
GEP20135804B (en) 2008-09-12 2013-04-10 Santen Pharmaceutical Co Ltd Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent
ES2745628T3 (es) 2008-11-07 2020-03-03 Univ Sheffield Medicamento y método de diagnóstico
WO2012094618A1 (en) * 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
TW201422590A (zh) * 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (de) 2012-12-21 2016-04-27 Abbvie Inc Heterocyclische nuklearhormonrezeptormodulatoren
HK1252159A1 (zh) 2015-08-25 2019-05-17 参天制药株式会社 [4-(1,3,3-三甲基-2-氧代-3,4-二氢-1h-喹喔啉-7-基)苯氧基]乙基氧基化合物或其盐
WO2019180150A1 (en) 2018-03-22 2019-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
CA3102099C (en) 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス, インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
AU2021266739B2 (en) 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102911885B1 (ko) 2020-05-06 2026-01-12 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체
JP7853982B2 (ja) 2020-12-21 2026-04-30 コーセプト セラピューティクス, インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体調節因子を調製する方法
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683091A (en) 1967-11-13 1972-08-08 Wataru Nagata Certain phenanthrene compounds for treatment of acne
JPS50111098A (de) 1974-02-18 1975-09-01
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
JPH06263688A (ja) 1991-09-04 1994-09-20 Otsuka Pharmaceut Factory Inc フェナンスレン誘導体
EP0676196A1 (de) 1993-10-13 1995-10-11 Otsuka Pharmaceutical Co., Ltd. Stickstoffmonoxid-synthese-inhibitoren
DK0683172T3 (da) 1994-05-19 1998-03-30 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnanderivater
JPH0952899A (ja) 1994-09-30 1997-02-25 Tsumura & Co ロイコトリエン拮抗剤
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5767113A (en) 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
WO1998027986A1 (en) 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EP0903146A1 (de) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
KR20010040935A (ko) 1998-02-13 2001-05-15 스티븐 에프. 웨인스톡 글루코코르티코이드 선택적인 소염제
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
WO1999063976A2 (en) 1998-06-08 1999-12-16 Karo Bio Ab Liver-selective glucocorticoid antagonist for treating diabetes
JP4676061B2 (ja) 1998-07-30 2011-04-27 アボット・ラボラトリーズ グルココルチコイド選択性薬剤
GB9816935D0 (en) 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
PL207610B1 (pl) * 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny

Also Published As

Publication number Publication date
MXPA01011108A (es) 2002-06-04
BR0104834A (pt) 2002-08-20
DE60113032T2 (de) 2006-07-06
ES2246292T3 (es) 2006-02-16
CA2360313A1 (en) 2002-04-30
EP1201660B1 (de) 2005-08-31
US20040014741A1 (en) 2004-01-22
DE60113032D1 (de) 2005-10-06
US6852719B2 (en) 2005-02-08
JP2002193955A (ja) 2002-07-10
EP1201660A1 (de) 2002-05-02
CA2360313C (en) 2006-12-05

Similar Documents

Publication Publication Date Title
DE60113032D1 (de) Glucocorticoid Rezeptor Modulatoren
DE60120077D1 (de) Modulatoren des Glucocorticoid-Rezeptors
AP1542A (en) Glucocorticoid receptor modulators.
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BR0313923A (pt) Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
TNSN08027A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same
BRPI0509761B8 (pt) compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
BR0115291A (pt) Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
BRPI0414643A (pt) composto, composições farmacêuticas, e, uso de um composto
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
BR9905974A (pt) Derivados de ácido aril carboxìlico e tetrazol
ATE434437T1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties